Cargando…

Current advances in biomarkers for targeted therapy in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. Compared to other breast cancer subtypes, TNBC is more aggressive, has a higher pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleisher, Brett, Clarke, Charlotte, Ait-Oudhia, Sihem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063595/ https://www.ncbi.nlm.nih.gov/pubmed/27785100 http://dx.doi.org/10.2147/BCTT.S114659

Ejemplares similares

In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
por: Fleisher, Brett, et al.
Publicado: (2021)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
por: Fleisher, Brett, et al.
Publicado: (2017)

Chloroquine sensitizes MDA-MB-231 cells to osimertinib through autophagy–apoptosis crosstalk pathway
por: Fleisher, Brett, et al.
Publicado: (2019)

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
por: Kamta, Jeff, et al.
Publicado: (2017)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
por: Franco, Yesenia L, et al.
Publicado: (2018)

Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer
por: Ande, Anusha, et al.
Publicado: (2018)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
por: Robainas, Marianela, et al.
Publicado: (2017)

Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer
por: Dias, Cristina J., et al.
Publicado: (2021)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach
por: Mody, Hardik, et al.
Publicado: (2023)

New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
por: El Hejjioui, Brahim, et al.
Publicado: (2023)

In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization
por: Mody, Hardik, et al.
Publicado: (2023)

Triple-negative breast cancer: promising prognostic biomarkers currently in development
por: Sukumar, Jasmine, et al.
Publicado: (2021)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Recent advances in targeted strategies for triple-negative breast cancer
por: Zhu, Shuangli, et al.
Publicado: (2023)

Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer
por: Fatima, Mahak, et al.
Publicado: (2022)

Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)

Novel therapy for locally advanced triple-negative breast cancer
por: YAMADA, ATSUKO, et al.
Publicado: (2015)

RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer
por: Haque, Sakib, et al.
Publicado: (2021)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
por: Mina, Alain, et al.
Publicado: (2017)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)

Triple-negative breast cancer therapy: Current and future perspectives (Review)
por: Won, Kwang-Ai, et al.
Publicado: (2020)

A review of current progress in triple-negative breast cancer therapy
por: Shen, Meiying, et al.
Publicado: (2020)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
por: Shi, Jinhong, et al.
Publicado: (2020)

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
por: Pradhan, Rajesh, et al.
Publicado: (2023)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

RNA nanoparticles for targeted therapies of triple-negative breast cancers
por: Danai, Leyla, et al.
Publicado: (2023)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin
por: Mody, Hardik, et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
por: Miao, Xin, et al.
Publicado: (2016)

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies
por: MacDonald, Isaiah, et al.
Publicado: (2022)

Current approaches in treatment of triple-negative breast cancer
por: Wahba, Hanan Ahmed, et al.
Publicado: (2015)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
por: Gupta, Gagan K., et al.
Publicado: (2020)

Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
por: Chapdelaine, Abygail G., et al.
Publicado: (2023)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer
por: Elbaz, Mohamad, et al.
Publicado: (2016)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_75gn6v4914ujq6undh1oncd1sc